Scarica l'app Stockscreener
25.14
4.93%
-1.305
Dopo l'orario di chiusura:
25.09
-0.05
-0.20%
Precedente Chiudi:
$26.45
Aprire:
$26.49
Volume 24 ore:
282.79K
Relative Volume:
0.94
Capitalizzazione di mercato:
$1.13B
Reddito:
$45.95M
Utile/perdita netta:
$-48.88M
Rapporto P/E:
-22.59
EPS:
-1.1129
Flusso di cassa netto:
$109.67M
1 W Prestazione:
-12.65%
1M Prestazione:
-8.58%
6M Prestazione:
+76.05%
1 anno Prestazione:
+293.43%
Intervallo 1D:
$24.96
$27.02
Intervallo di 1 settimana:
$24.96
$30.00
Portata 52W:
$4.66
$32.63
Septerna Inc Stock (SEPN) Company Profile
Nome
Septerna Inc
Settore
Industria
Telefono
650-338-3533
Indirizzo
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
25.14 | 1.13B | 45.95M | -48.88M | 109.67M | -1.1129 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-19 | Iniziato | Raymond James | Strong Buy |
| 2025-12-15 | Iniziato | Truist | Buy |
| 2025-11-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-11-19 | Iniziato | JP Morgan | Overweight |
| 2024-11-19 | Iniziato | TD Cowen | Buy |
| 2024-11-19 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Septerna Inc Borsa (SEPN) Ultime notizie
What is HC Wainwright's Forecast for Septerna Q1 Earnings? - MarketBeat
Analysts Conflicted on These Technology Names: Fortinet (FTNT), Septerna, Inc. (SEPN) and Oracle (ORCL) - The Globe and Mail
Septerna (SEPN) Q4 Loss Despite Revenue Surge Reinforces Bearish Profitability Narrative - simplywall.st
Truist Lifts Price Target on Septerna to $35 From $34, Keeps Buy Rating - marketscreener.com
Cantor Fitzgerald Maintains Overweight on Septerna, Inc. (SEPN) March 2026 - Meyka
Truist raises Septerna stock price target to $35 on trial progress - Investing.com
Cantor Fitzgerald reiterates Septerna stock rating on platform value By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Septerna stock rating on platform value - Investing.com
Septerna (SEPN) Reports Narrower Q4 Loss of $0.24/Share as Revenue Climbs to $24.1M - AlphaStreet
Septerna beats fourth quarter loss estimates on collaboration revenue By Investing.com - Investing.com India
Septerna beats fourth quarter loss estimates on collaboration revenue - Investing.com
Assessing Septerna (SEPN) Valuation After Earnings Progress And Positive SEP-631 Phase 1 Results - Sahm
Decoding Septerna Inc (SEPN): A Strategic SWOT Insight - GuruFocus
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates - Bitget
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Earnings Flash (SEPN) Septerna Posts Q4 Loss $-0.24, vs. FactSet Est of Loss of $-0.24 - marketscreener.com
Biotech firm Septerna beats Q4 revenue expectations, net loss narrows - TradingView
Earnings Summary: Septerna Q4 - Benzinga
Septerna, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings Flash (SEPN) Septerna, Inc. Reports Q4 Revenue $24.1M, vs. FactSet Est of $18.2M - marketscreener.com
SEPN SEC FilingsSepterna, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
How Investors May Respond To Septerna (SEPN) Advancing SEP-631 Into Phase 2b Urticaria Trials - simplywall.st
Can Septerna Inc. stock hit record highs againEarnings Performance Report & Fast Exit Strategy with Risk Control - Naître et grandir
Insider Selling: Septerna (NASDAQ:SEPN) Insider Sells 70,453 Shares of Stock - MarketBeat
Septerna Executive Sells Shares - TradingView
Wells Fargo Sticks to Its Buy Rating for Septerna, Inc. (SEPN) - The Globe and Mail
SEPN: SEP-631 advances to phase II in CSU after robust phase I results; SEP-479 enters clinical trials - TradingView
SEPN: SEP-631 and SEP-479 advance with strong data, phase 2 and 1 trials planned, and pipeline growth - TradingView
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN), Payoneer (PAYO) and Porch Group (PRCH) - The Globe and Mail
Septerna Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Sahm
A Look At Septerna (SEPN) Valuation After Recent Share Price Momentum And GPCR Pipeline Reassessment - Sahm
Septerna (SEPN) Receives Overweight Rating and Target Price Hike by Wells Fargo | SEPN Stock News - GuruFocus
Wells Fargo & Company Increases Septerna (NASDAQ:SEPN) Price Target to $48.00 - MarketBeat
Does SEP-631’s Phase 1 Proof-of-Mechanism and 2026 Trial Plan Reshape Septerna’s Mast Cell Strategy (SEPN)? - Yahoo Finance
[144] Septerna, Inc. SEC Filing - Stock Titan
Septerna (NASDAQ:SEPN) Price Target Raised to $40.00 at HC Wainwright - MarketBeat
Septerna Advances SEP-631 After Positive Phase 1 Results - TipRanks
SEPN: SEP-631 showed strong Phase 1 efficacy and safety, advancing to Phase 2 for urticaria in 2026 - TradingView
Septerna reports positive Phase 1 SEP-631 data; plans Phase 2b CSU study in 2H 2026 - TradingView
Positive SEP-631 trial data drives Phase 2 plan at Septerna (NASDAQ: SEPN) - Stock Titan
Septerna’s SEP-631 shows positive Phase 1 trial results - Investing.com Australia
Septerna’s SEP-631 shows positive Phase 1 trial results By Investing.com - Investing.com South Africa
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy - Bitget
Septerna says SEP-631 well-tolerated with adverse event profile comparable to placebo - marketscreener.com
Septerna Says SEP-631 Well-Tolerated With Adverse Event Profile Comparable To Placebo - TradingView
Septerna pill blocked induced skin wheals at low doses in Phase 1 test - Stock Titan
Sentiment Watch: Is Septerna Inc part of any ETFBear Alert & Free Community Consensus Stock Picks - baoquankhu1.vn
Why Septerna (SEPN) Is Up 6.4% After Surging GPCR Pipeline-Driven Revenue GrowthAnd What's Next - simplywall.st
Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Septerna, Inc. (SEPN) Stock Analysis: Unleashing a 12,113% Revenue Growth Amidst Biotech Innovations - DirectorsTalk Interviews
Zacks Research Upgrades Septerna (NASDAQ:SEPN) to Hold - MarketBeat
Septerna Inc Azioni (SEPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):